Study findings from University of Texas, M. D. Anderson Cancer Center broaden understanding of prostate cancer prevention
2007 NOV 19 -- Scientists discuss in 'Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases' new findings in prostate cancer. In this recently published study, investigators in the United States conducted a study "To further assess preclinical and early clinical evidence that imatinib mesylate, a platelet-derived growth factor receptor (PDGFR) inhibitor, modulates taxane activity in prostate cancer and bone metastases, a randomized study was conducted Men with progressive castration-resistant prostate cancer with bone metastases (n=144) were planned for equal randomization to i.v. 30 mg/m2 docetaxel on days 1, 8, 15, and 22 every 42 days with 600 mg imatinib daily or placebo, for an improvement in median progression-free survival from 4.5 to 7.5 months (two-sided alpha=0.05 and beta=0.20). Secondary end points included differential toxicity and bone turnover markers, tumor phosphorylated PDGFR (p-PDGFR) expression, and modulation of p-PDGFR in peripheral blood leukocytes Accrual was halted early because of adverse gastrointestinal events." "Among 116 evaluable men (57 docetaxel + imatinib; 59 docetaxel + placebo), respective median times to progression were 4.2 months (95% confidence interval, 3.1-7.5) and 4.2 months (95% confidence interval, 3.0-6.8; p=0.58, log-rank test). Excess grade 3 toxicities (n=23) in the docetaxel + imatinib group were principally fatigue and gastrointestinal. Tumor p-PDGFR expression was observed in 12 of 14 (86%) evaluable bone specimens. In peripheral blood leukocytes, p-PDGFR reduction was more likely in docetaxel + imatinib-treated patients compared with docetaxel + placebo (p <0.0001), as were reductions in urine N-telopeptides (p=0.004) but not serum bone-specific alkaline phosphatase (p=0.099) These clinical and translational results question the value of PDGFR inhibition with taxane chemotherapy in prostate cancer bone metastases and are at variance with the preclinical studies," wrote P. Mathew and colleagues, University of Texas, M. D. Anderson Cancer Center. The researchers concluded: "This discordance requires explanation." Mathew and colleagues published their study in Clinical Cancer Research (Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical Cancer Research, 2007;13(19):5816-24). For additional information, contact P. Mathew, The University of Texas M D Anderson Cancer Center, Dept. of Genitourinary Medical Oncology, Houston, Texas 77030 USA.. The publisher of the journal Clinical Cancer Research can be contacted at: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. Keywords: United States, Houston, Prostate Cancer Prevention, Antineoplastic, Cancer Research, Chemotherapy, Clinical Trials, Docetaxel, Drug Therapy, Drugs, Hematology, Imatinib Mesylate, Oncology, Pharmaceuticals, Pre-Trials Research, Prostate Cancer, Prostatic Neoplasms, Protein Kinase Inhibitor, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
